Bafilomycin A1 (Baf-A1)

Bafilomycin A1 (Baf-A1) is an inhibitor of ATPases and V-ATPase and related targets used in studies of Apoptosis and Autophagy. In practice, this places the compound in experiments that measure caspase-associated cell-death signaling and survival decisions and autophagic flux, lysosomal turnover, and stress adaptation in apoptosis, autophagy, and cancer models.

By inhibiting ATPases and V-ATPase and related targets, Bafilomycin A1 (Baf-A1) can be used to examine caspase-associated cell-death signaling and survival decisions and autophagic flux, lysosomal turnover, and stress adaptation. The enzyme annotation adds relevance to enzyme-activity assays, substrate-conversion studies, and mechanism profiling, together with downstream-response mapping in the same experimental setting. In apoptosis, autophagy, and cancer models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving ATPases and V-ATPase and related targets
• Pathway perturbation studies connected to Apoptosis and Autophagy
• Concentration-response inhibition and target-dependence studies
• Enzyme-activity assays, substrate-conversion studies, and mechanism profiling

Overall, Bafilomycin A1 (Baf-A1) is appropriate when a defined chemical perturbant is needed to connect ATPases and V-ATPase and related targets with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, autophagy, and cancer models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.